Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Brief Summary: The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).


Options:
A: Arm Label: Pts with B Cell Acute Lymphoblastic Leukemia; Type: EXPERIMENTAL; Interventions: Biological: gene-modified T cells targeted | Intervention Type: BIOLOGICAL; Name: gene-modified T cells targeted; Assigned to Arm(s): Pts with B Cell Acute Lymphoblastic Leukemia
B: Arm Label: Treatment (cellular adoptive immunotherapy following PBSCT); Type: EXPERIMENTAL; Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation, Biological: Filgrastim, Biological: Genetically Engineered Lymphocyte Therapy, Other: Laboratory Biomarker Analysis, Procedure: Peripheral Blood Stem Cell Transplantation, Drug: Plerixafor, Biological: Rituximab | Intervention Type: PROCEDURE; Name: Autologous Hematopoietic Stem Cell Transplantation; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Genetically Engineered Lymphocyte Therapy; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell Transplantation; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: DRUG; Name: Plerixafor; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT)
C: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel
D: Arm Label: Axicabtagene Ciloleucel Treatment; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Cyclophosphamide, Drug: Fludarabine | Arm Label: Standard of Care Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders. | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Axicabtagene Ciloleucel Treatment | Intervention Type: DRUG; Name: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.; Assigned to Arm(s): Standard of Care Therapy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Axicabtagene Ciloleucel Treatment | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Axicabtagene Ciloleucel Treatment

Answer: D